Impact of Metformin on Immunity

The University of Texas Health Science Center at San Antonio18 enrolled

Overview

To determine whether metformin (MET) can improve the immune response to the pneumococcal conjugate vaccine (PCV-13) in older adults.

The objective of this study is to determine whether metformin (MET) can improve the immune response to the pneumococcal conjugate vaccine (PCV-13) in older adults, and if this effect is mediated by the gut microbiota. The proposed research projects will provide the necessary pilot data for future, more definitive, studies that will evaluate the impact of immunomodulatory therapies, such as MET therapy, on the aging immune system. The specific aims are: Aim 1. Compare PCV13 vaccine response in elderly adults (≥63 years of age) treated with MET vs. placebo. For this study, 50 elderly volunteers will be enrolled and randomly assigned to receive MET or placebo. The hypothesis that MET can improve vaccine responsiveness by measuring serotype-specific IgG concentrations before and 30 days after PCV13 administration will be tested. Aim 2. Determine whether the frequencies of immunophenotypes differ between elderly adults treated with MET vs. placebo. The mechanisms of MET's effect on the immune system by comparing immunophenotypes of MET and placebo groups between baseline and prior to PCV13 and between baseline and 30 days after PCV13 administration will be explored.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Enrollment

Conditions

Aging Vaccine Response Impaired

Interventions

MetforminDRUG

Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.

PlaceboDRUG

Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks

Eligibility

Sex: ALLMin age: 63 YearsMax age: 90 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age 63 to 89 years of age 2. No history of pneumococcal vaccinations 3. Able to take oral medications 4. Able to provide informed consent 5. Not currently taking metformin Exclusion Criteria: 1. Previous vaccination with any pneumococcal vaccine 2. Metformin within the last 6 months 3. Contraindication for PCV13 4. History of severe adverse reaction associated with any vaccine component 5. Residence in long-term care facility 6. Diagnosis of diabetes (diagnosis of pre-diabetes okay) 7. Chronic renal disease (or eGFR \<50 mL/min) or renal failure (defined as receipt of renal dialysis or transplant) or nephrotic syndrome 8. History of adverse reaction or contraindications associated with metformin 9. Recent history or plan for radiocontrast 10. Self-reported dementia or severe cognitive impairment 11. Receipt of blood products within 6 months before enrollment 12. History of heart disease (New York Heart Classification greater than class II; more than non-specific ST-T wave changes on the ECG) 13. History of chronic obstructive pulmonary disease 14. Poorly controlled blood pressure (systolic BP\>160, diastolic BP\>90 mmHg) 15. History of an immunodeficiency 16. Use of use of investigational products, antibiotics, probiotics, or systemic immunosuppressive therapy (systemic steroids) within 1 month of study start; patients who are taking these medications chronically, with no expected discontinuation during the study period would not be considered ineligible. 17. Treatment with anticoagulants (warfarin) 18. Donated blood within the last 2 months 19. Subject is considered unsuitable for the study in the opinion of the investigator for any other reason

Locations (1)

UT Health San Antonio

San Antonio, Texas, United States

Outcomes

Primary Outcomes

Change in antibody responses to PCV13

The primary outcome will be antibody responses to PCV13. Antibody levels of each of the 13 different serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) will be compared between the pre-treatment values and the post treatment values.

Time frame: Change from 4 weeks to 8 weeks

Secondary Outcomes

Measure of immunophenotypes

The distribution of immunophenotypes will be presented descriptively at each time point for each treatment group. To determine which immunophenotypes differed between MET and placebo groups, changes will be determined using within-patient cell count ratios for each measured phenotype between baseline and 6-weeks of study drug treatment and between baseline and the 30 days after PCV13.

Time frame: Baseline, 4 weeks and 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.